About this Journal Submit a Manuscript Table of Contents
Journal of Obesity
Volume 2013 (2013), Article ID 296537, 8 pages
http://dx.doi.org/10.1155/2013/296537
Research Article

Altered Hepatic Lipid Metabolism Contributes to Nonalcoholic Fatty Liver Disease in Leptin-Deficient Ob/Ob Mice

1Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO 65211, USA
2Department of Food Science, University of Missouri, Columbia, MO 65211, USA
3Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri, Columbia, MO 65211, USA
4Harry S. Truman Memorial Veterans' Medical Center, Columbia, MO 65201, USA

Received 2 October 2012; Accepted 17 December 2012

Academic Editor: Ahmed Almobarak

Copyright © 2013 James W. Perfield II et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., “Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity,” Hepatology, vol. 40, no. 6, pp. 1387–1395, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. R. S. Rector, J. P. Thyfault, Y. Wei, and J. A. Ibdah, “Non-alcoholic fatty liver disease and the metabolic syndrome: an update,” World Journal of Gastroenterology, vol. 14, no. 2, pp. 185–192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Cusi, “Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications,” Gastroenterology, vol. 142, no. 4, pp. 711–725, 2012. View at Publisher · View at Google Scholar
  4. L. Hebbard and J. George, “Animal models of nonalcoholic fatty liver disease,” Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 1, pp. 34–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. R. M. London and J. George, “Pathogenesis of NASH: animal models,” Clinics in Liver Disease, vol. 11, no. 1, pp. 55–74, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Takahashi, Y. Soejima, and T. Fukusato, “Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis,” World Journal of Gastroenterology, vol. 18, no. 19, pp. 2300–2308, 2012. View at Publisher · View at Google Scholar
  7. R. S. Rector, J. P. Thyfault, G. M. Uptergrove et al., “Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model,” Journal of Hepatology, vol. 52, no. 5, pp. 727–736, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Tschöp and M. L. Heiman, “Rodent obesity models: an overview,” Experimental and Clinical Endocrinology and Diabetes, vol. 109, no. 6, pp. 307–319, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Wolf, “Insulin resistance associated with leptin deficiency in mice: a possible model for noninsulin-dependent diabetes mellitus,” Nutrition Reviews, vol. 59, no. 6, pp. 177–179, 2001. View at Scopus
  10. J. Xu, S. R. Kulkarni, A. C. Donepudi, V. R. More, and A. L. Slitt, “Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice,” Diabetes, vol. 61, no. 12, pp. 3208–3218, 2012.
  11. I. García-Ruiz, C. Rodríguez-Juan, T. Díaz-Sanjuan et al., “Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice,” Hepatology, vol. 44, no. 3, pp. 581–591, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Monsenego, A. Mansouri, M. Akkaoui et al., “Enhancing liver mitochondrial fatty acid oxidation capacity in obese mice improves insulin sensitivity independently of hepatic steatosis,” Journal of Hepatology, vol. 56, no. 3, pp. 632–639, 2012.
  13. Q. M. Anstee and R. D. Goldin, “Mouse models in non-alcoholic fatty liver disease and steatohepatitis research,” International Journal of Experimental Pathology, vol. 87, no. 1, pp. 1–16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. R. S. Rector, J. P. Thyfault, R. T. Morris et al., “Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 294, no. 3, pp. G619–G626, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. S. Rector, G. M. Uptergrove, E. Matthew Morris et al., “Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 300, no. 5, pp. G874–G883, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Schwartz and N. E. Wolins, “A simple and rapid method to assay triacylglycerol in cells and tissues,” Journal of Lipid Research, vol. 48, no. 11, pp. 2514–2520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. R. S. Rector, J. P. Thyfault, M. J. Laye et al., “Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long-Evans Tokushima Fatty (OLETF) rats,” Journal of Physiology, vol. 586, no. 17, pp. 4241–4249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Anderson and J. Borlak, “Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis,” Pharmacological Reviews, vol. 60, no. 3, pp. 311–357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. S. Garfield, C. Patterson, S. Skora et al., “Neurochemical characterization of body weight-regulating leptin receptor neurons in the nucleus of the solitary tract,” Endocrinology, vol. 153, no. 10, pp. 4600–4607, 2012. View at Publisher · View at Google Scholar
  20. M. W. Schwartz, D. G. Baskin, T. R. Bukowski et al., “Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice,” Diabetes, vol. 45, no. 4, pp. 531–535, 1996. View at Scopus
  21. V. Trak-Smayra, V. Paradis, J. Massart, S. Nasser, V. Jebara, and B. Fromenty, “Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet,” International Journal of Experimental Pathology, vol. 92, no. 6, pp. 413–421, 2011. View at Publisher · View at Google Scholar
  22. S. Bellentani, F. Scaglioni, M. Marino, and G. Bedogni, “Epidemiology of non-alcoholic fatty liver disease,” Digestive Diseases, vol. 28, no. 1, pp. 155–161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Schattenberg and P. R. Galle, “Animal models of non-alcoholic steatohepatitis: of mice and man,” Digestive Diseases, vol. 28, no. 1, pp. 247–254, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Fujii and N. Kawada, “Inflammation and fibrogenesis in steatohepatitis,” Journal of Gastroenterology, vol. 47, no. 3, pp. 215–225, 2012. View at Publisher · View at Google Scholar
  25. B. T. Bikman, “A role for sphingolipids in the pathophysiology of obesity-induced inflammation,” Cellular and Molecular Life Sciences, vol. 69, no. 13, pp. 2135–2146, 2012. View at Publisher · View at Google Scholar
  26. I. Shimomura, Y. Bashmakov, and J. D. Horton, “Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus,” Journal of Biological Chemistry, vol. 274, no. 42, pp. 30028–30032, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Diraison, P. H. Moulin, and M. Beylot, “Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease,” Diabetes and Metabolism, vol. 29, no. 5, pp. 478–485, 2003. View at Scopus
  28. K. L. Donnelly, C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks, “Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1343–1351, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. J. M. Schwarz, P. Linfoot, D. Dare, and K. Aghajanian, “Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets,” American Journal of Clinical Nutrition, vol. 77, no. 1, pp. 43–50, 2003. View at Scopus
  30. R. Dentin, F. Benhamed, I. Hainault et al., “Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice,” Diabetes, vol. 55, no. 8, pp. 2159–2170, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. K. F. Petersen, S. Dufour, D. Befroy, M. Lehrke, R. E. Hendler, and G. I. Shulman, “Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes,” Diabetes, vol. 54, no. 3, pp. 603–608, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. K. M. Utzschneider and S. E. Kahn, “Review: the role of insulin resistance in nonalcoholic fatty liver disease,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 12, pp. 4753–4761, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Wei, R. S. Rector, J. P. Thyfault, and J. A. Ibdah, “Nonalcoholic fatty liver disease and mitochondrial dysfunction,” World Journal of Gastroenterology, vol. 14, no. 2, pp. 193–199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Cohen, M. Miyazaki, N. D. Socci et al., “Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss,” Science, vol. 297, no. 5579, pp. 240–243, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. S. B. Biddinger, M. Miyazaki, J. Boucher, J. M. Ntambi, and C. R. Kahn, “Leptin suppresses stearoyl-CoA desaturase 1 by mechanisms independent of insulin and sterol regulatory element-binding protein-1c,” Diabetes, vol. 55, no. 7, pp. 2032–2041, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. T. R. Koves, P. Li, J. An et al., “Peroxisome proliferator-activated receptor-γ co-activator 1α-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency,” Journal of Biological Chemistry, vol. 280, no. 39, pp. 33588–33598, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. J. P. Thyfault, M. G. Cree, D. Zheng et al., “Contraction of insulin-resistant muscle normalizes insulin action in association with increased mitochondrial activity and fatty acid catabolism,” American Journal of Physiology-Cell Physiology, vol. 292, no. 2, pp. C729–C739, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Aureli, C. Puccetti, M. E. Di Cocco et al., “Entry of [(1,2-13C2)acetyl]-L-carnitine in liver tricarboxylic acid cycle and lipogenesis. A study by 13C NMR spectroscopy in conscious, freely moving rats,” European Journal of Biochemistry, vol. 263, no. 1, pp. 287–293, 1999. View at Publisher · View at Google Scholar · View at Scopus